Abstract
Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-β (Aβ) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce Aβ indicate dysregulation of production or clearance of Aβ. Whether dysregulation of Aβ synthesis or clearance causes the most common form of Alzheimer disease (sporadic, >99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of Aβ in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wolfe, R.R. Regulation of skeletal muscle protein metabolism in catabolic states. Curr. Opin. Clin. Nutr. Metab. Care 8, 61–65 (2005).
San Pietro, A. & Rittenberg, D. A study of the rate of protein synthesis in humans. II. Measurement of the metabolic pool and the rate of protein synthesis. J. Biol. Chem. 201, 457–473 (1953).
Yarasheski, K.E. Exercise, aging, and muscle protein metabolism. J. Gerontol. A Biol. Sci. Med. Sci. 58, M918–M922 (2003).
Elias, N., Patterson, B.W. & Schonfeld, G. In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene. Arterioscler. Thromb. Vasc. Biol. 20, 1309–1315 (2000).
Owen, F. et al. Insertion in prion protein gene in familial Creutzfeldt-Jakob disease. Lancet 1, 51–52 (1989).
Polymeropoulos, M.H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047 (1997).
Hutton, M. et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702–705 (1998).
Podlisny, M.B., Lee, G. & Selkoe, D.J. Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. Science 238, 669–671 (1987).
Golde, T.E., Eckman, C.B. & Younkin, S.G. Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta 1502, 172–187 (2000).
Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741–766 (2001).
Gravina, S.A. et al. Amyloid beta protein (Abeta) in Alzheimer's disease brain. J. Biol. Chem. 270, 7013–7016 (1995).
Wisniewski, K.E., Wisniewski, H.M. & Wen, G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17, 278–282 (1985).
Fishman, R.A. Cerebrospinal Fluid in Diseases of the Nervous System. (Saunders, Philadelphia, 1992).
Yarasheski, K.E. et al. Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am. J. Physiol. 275, E577–E583 (1998).
Smith, Q.R., Momma, S., Aoyagi, M. & Rapoport, S.I. Kinetics of neutral amino acid transport across the blood-brain barrier. J. Neurochem. 49, 1651–1658 (1987).
Wolfe, R.R., Chinkes, D.L. & Wolfe, R.R. Isotope Tracers In Metabolic Research: Principles and Practice of Kinetic Analysis. (Wiley-Liss, Hoboken, New Jersey, 2005).
Zlokovic, B.V. et al. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem. Biophys. Res. Commun. 197, 1034–1040 (1993).
DeMattos, R.B. et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855 (2001).
Poduslo, J.F., Curran, G.L., Wengenack, T.M., Malester, B. & Duff, K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 555–567 (2001).
Saido, T.C. Aβ Metabolism and Alzheimer's Disease. (Landes Bioscience, 2003).
Lanz, T.A., Hosley, J.D., Adams, W.J. & Merchant, K.M. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo -6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J. Pharmacol. Exp. Ther. 309, 49–55 (2004).
Siemers, E. et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28, 126–132 (2005).
Yarasheski, K.E., Smith, K., Rennie, M.J. & Bier, D.M. Measurement of muscle protein fractional synthetic rate by capillary gas chromatography/combustion isotope ratio mass spectrometry. Biol. Mass Spectrom. 21, 486–490 (1992).
Merchak, A., Patterson, B.W., Yarasheski, K.E. & Hamvas, A. Use of stable isotope labeling technique and mass isotopomer distribution analysis of [(13)C]palmitate isolated from surfactant disaturated phospholipids to study surfactant in vivo kinetics in a premature infant. J. Mass Spectrom. 35, 734–738 (2000).
Garlick, P.J., McNurlan, M.A. & Preedy, V.R. A rapid and convenient technique for measuring the rate of protein synthesis in tissues by injection of [3H]phenylalanine. Biochem. J. 192, 719–723 (1980).
Cirrito, J.R. et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 23, 8844–8853 (2003).
Williams, M.A. Spinal catheter insertion via seated lumbar puncture using a massage chair. Neurology 58, 1859–1860 (2002).
DeMattos, R.B. et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855 (2001).
Acknowledgements
This work was supported by grants from the American Academy of Neurology Foundation, US National Institutes of Health (NIH) grants ADRC (P50 AG05681), GCRC (MO1 RR00036), Mass Spectrometry Resource (NIH RR000954), the Clinical Nutrition Research Unit (NIH DK056341) and The Alan A. and Edith L. Wolff Charitable Trust. We are grateful to the participants for their time and to Eli Lilly for providing m266 antibody.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A provisional patent was filed by Washington University with Randall Bateman and David Holtzman as inventors on some of the methods described in this publication.
Rights and permissions
About this article
Cite this article
Bateman, R., Munsell, L., Morris, J. et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12, 856–861 (2006). https://doi.org/10.1038/nm1438
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1438
This article is cited by
-
Autophagy Regulation Attenuates Neuroinflammation and Cognitive Decline in an Alzheimer's Disease Mouse Model with Chronic Cerebral Hypoperfusion
Inflammation (2024)
-
Sustained meningeal lymphatic vessel atrophy or expansion does not alter Alzheimer’s disease-related amyloid pathology
Nature Cardiovascular Research (2024)
-
The neuroprotective N-terminal amyloid-β core hexapeptide reverses reactive gliosis and gliotoxicity in Alzheimer’s disease pathology models
Journal of Neuroinflammation (2023)
-
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
Signal Transduction and Targeted Therapy (2023)
-
Anti-amnesic and Neuroprotective Potential of Genistein Against Alzheimer’s Disease
Revista Brasileira de Farmacognosia (2023)